Pharma major Lupin announced the launch of its Clonidine Hydrochloride extended-release tablets, 0.1mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Clonidine Hydrochloride ER tablets is the generic equivalent of Concordia International Corp's Kapvay tablets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.

Kapvay tablets had annual sales of approximately USD 66 million in the US (IQVIA MAT December 2017).

Shares of the company gained Rs 6.5, or 0.8%, to settle at Rs 814.45. The total volume of shares traded was 154,072 at the BSE (Thursday).